BioView and Abbott have entered into a partnership agreement for the development of automated scanning solution to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced non-small cell lung cancer (NSCLC).
Under the agreement, BioView will perform studies to get regulatory approval for its Duet automated scanner to include an indication for automated imaging and analysis of Abbott’s Vysis ALK Break Apart FISH Probe Kit.
In addition, Abbott plans to use the automated scanning solution in its own clinical trials for future regulatory approval for end-to-end automation of the preparation, scanning and scoring of formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer tissue specimens, probed with the ALK Kit.
Both the partners plan to co-promote the scanner worldwide, after receiving regulatory approvals.
The partners are also planning to integrate BioView’s automated scanner to further automate Abbott’s future FISH assay.